QNRX QUOIN PHARMACEUTICALS LTD

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.

The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or for updates.

For further information, contact:

Investor Relations

PCG Advisory

Jeff Ramson



(646) 863-6341



EN
02/05/2024

Underlying

QNRXQUOIN PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOIN PHARMACEUTICALS LTD

 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for ...

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for...

2h / 56m 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Globa...

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) today highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregivers and clinicians impacted by Netherton Syndrome, a rare genetic disease with no approved treatment or cure. Rare Disease Da...

February 26, 2026 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan...

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if Approved Orphan Drug Designation Previously Granted by Both the U.S. Food and Drug Administration (FDA) and the European Medicines (EMA) Agency in 2025 ASHBURN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals L...

January 27, 2026 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Targe...

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others to Commence 1H 2026      ASHBURN, Va., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late c...

November 11, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 202...

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome  – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Mo...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch